Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months

IMPORTANCE: Evidence for the timing of booster vaccination after completion of BNT162b2 and CoronaVac primary vaccination is crucial to guide policy recommendations. OBJECTIVE: To compare the odds of symptomatic SARS-CoV-2 infection and COVID-19–related outcomes after heterologous and homologous boo...

Descripción completa

Detalles Bibliográficos
Autores principales: Low, Ee Vien, Tok, Peter Seah Keng, Husin, Masliyana, Suah, Jing Lian, Tng, Boon Hwa, Thevananthan, Thevesh, Appannan, Maheshwara Rao, Yahaya, Hazlina, Mohd Zin, Shahanizan, Muhamad Zin, Faizah, Sivasampu, Sheamini, Peariasamy, Kalaiarasu M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366545/
https://www.ncbi.nlm.nih.gov/pubmed/35947381
http://dx.doi.org/10.1001/jamanetworkopen.2022.26046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366545/
https://www.ncbi.nlm.nih.gov/pubmed/35947381
http://dx.doi.org/10.1001/jamanetworkopen.2022.26046

Ejemplares similares